Event-Free Survival (EFS)
Figure 3. · Panel EFS_Kaplan-Meier_plot
Panel EFS_Kaplan-Meier_plot 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Naval Daver, Paresh Vyas, Gerwin Huls, Hartmut Döhner, Sébastien Maury, Jan Novak, Cristina Papayannidis, Carmen Martínez Chamorro, Pau Montesinos, Rabin Niroula, Pierre Fenaux, Jordi Esteve, Shang-Ju Wu, Adrien De Voeght, Jiri Mayer, Peter J M Valk, Lisa Johnson, Mei Dong, Ke Liu, Sowmya Kuwahara, Kenneth Caldwell, Guru Subramanian Guru Murthy
Blood 146(5) 601-611
Patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC) have limited treatment options. The phase 3 ENHANCE-3 study aimed to determine whether magrolimab (magrolimab arm) was superior to placebo (control arm) when either was combined with venetoclax and azacitidine. Adults with previously untreated AML who were ineligible for IC were randomized to receive magrolimab (1 mg/kg on days 1 and 4, 15 mg/kg on day 8, 30 mg/kg on days 11 and 15, then weekly for 5 weeks, and then every 2 weeks) or placebo, venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter), and azacitidine (75 mg/m2 days 1-7) in 28-day cycles. The primary end point was overall survival (OS); key secondary end points included complete remission (CR) rate and safety. After randomization of 378 patients, the trial was stopped at a prespecified interim analysis owing to futility. At final analysis, with median follow-up of 7.6 months (magrolimab arm) vs 7.4 months (control arm), median OS was 10.7 vs 14.1 months (hazard ratio, 1.178; 95% confidence interval, 0.848-1.637). The CR rate within 6 cycles was 41.3% vs 46.0%. Addition of magrolimab to venetoclax and azacitidine resulted in more fatal adverse events (19.0% vs 11.4%), primarily driven by grade 5 infections (11.1% vs 6.5%) and respiratory events (2.6% vs 0%). There were similar incidences of any-grade infections, febrile neutropenia, and neutropenia between arms. These results highlight the difficulty in improving outcomes for patients with AML who were ineligible for IC. This trial was registered at www.clinicaltrials.gov as #NCT05079230.
1 个 Figure · 1 个 KM 面板
EFS. IQR, interquartile range.
Figure 3. · Panel EFS_Kaplan-Meier_plot
Panel EFS_Kaplan-Meier_plot 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。